| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 112, 1000-1006, Copyright © 1983 by Endocrine Society
ARTICLES |
R Podbesek, C Edouard, PJ Meunier, JA Parsons, J Reeve, RW Stevenson and JM Zanelli
The adult greyhound was found to be similar to adult man with respect to kinetic and histomorphometric indices of calcium metabolism. The relationship between trabecular bone tissue balance and the pattern of human PTH fragment 1-34 (hPTH 1-34) administration by daily injections or continuous sc infusions was investigated in this model and the results compared to those from a clinical trial of hPTH 1-34 in involutional osteoporosis (peptide administration by single daily injections). In the dogs, the daily injection regime elevated plasma levels of immunoreactive hPTH 1-34 for no more than 4 h/day. The greyhounds so treated showed significantly increased indices of bone formation (surface osteoid, plasma alkaline phosphatase activity, and skeletal accretion rate of calcium) and resorption (number of osteoclasts, resorption surfaces). Iliac trabecular bone volume increased significantly, as it did in the patients. The infusions did not significantly increase the trabecular bone volume or the 47Ca accretion rate, two parameters which increased in parallel in dogs and patients treated successfully by daily injections. The osteoclastic surfaces, however, were clearly increased by continuous infusions, while the increases in the osteoblastic surfaces were less statistically significant. Since hPTH 1-34 may inhibit osteogenesis in Friedenstein chambers, it is possible that the increased osteoblastic activity induced by the daily injection regime in trabecular bone is dependent on the noncontinuous nature of the PTH stimulus.
This article has been cited by other articles:
![]() |
F. Joseph, B. Y. Chan, B. H. Durham, A. M. Ahmad, S. Vinjamuri, J. A. Gallagher, J. P. Vora, and W. D. Fraser The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3230 - 3238. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Little, M. Ramachandran, and A. Schindeler The anabolic and catabolic responses in bone repair J Bone Joint Surg Br, April 1, 2007; 89-B(4): 425 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. Alkhiary, L. C. Gerstenfeld, E. Krall, M. Westmore, M. Sato, B. H. Mitlak, and T. A. Einhorn Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34) J. Bone Joint Surg. Am., April 1, 2005; 87(4): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. A. Rosei, D. Valle, N. Iori, J. P Bilezikian, J. D Veldhuis, and A. Giustina Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects Eur. J. Endocrinol., February 1, 2005; 152(2): 199 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Madore, P. J. Sherman, and J. M. Lane Parathyroid Hormone J. Am. Acad. Ortho. Surg., March 1, 2004; 12(2): 67 - 71. [Full Text] [PDF] |
||||
![]() |
K. H. Mikulec, L. Holloway, R. E. Krasnow, H. Javitz, G. E. Swan, T. Reed, R. Marcus, and D. Carmelli Relationship of Endogenous Sex Hormones to Coronary Heart Disease: A Twin Study J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1240 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A Cappuzzo and J. C Delafuente Teriparatide for Severe Osteoporosis Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. W. Chan, S.-C. Tiu, K.-L. Choi, C.-H. Choi, A. P. S. Kong, and C.-C. Shek Increased Bone Mineral Density in Patients with Chronic Hypoparathyroidism J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3155 - 3159. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ahmad, J. Thomas, A. Clewes, M. T. Hopkins, R. Guzder, H. Ibrahim, B. H. Durham, J. P. Vora, and W. D. Fraser Effects of Growth Hormone Replacement on Parathyroid Hormone Sensitivity and Bone Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2860 - 2868. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lotinun, J. D. Sibonga, and R. T. Turner Triazolopyrimidine (Trapidil), a Platelet-Derived Growth Factor Antagonist, Inhibits Parathyroid Bone Disease in an Animal Model for Chronic Hyperparathyroidism Endocrinology, May 1, 2003; 144(5): 2000 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Crandall Parathyroid Hormone for Treatment of Osteoporosis Arch Intern Med, November 11, 2002; 162(20): 2297 - 2309. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Neer, C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich, J.-Y. Reginster, A. B. Hodsman, E. F. Eriksen, S. Ish-Shalom, H. K. Genant, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis N. Engl. J. Med., May 10, 2001; 344(19): 1434 - 1441. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tetradis, O. Bezouglaia, and A. Tsingotjidou Parathyroid Hormone Induces Expression of the Nuclear Orphan Receptor Nurr1 in Bone Cells Endocrinology, February 1, 2001; 142(2): 663 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-P. Yu and S. Chandrasekhar Parathyroid Hormone (PTH 1-34) Regulation of Rat Osteocalcin Gene Transcription Endocrinology, August 1, 1997; 138(8): 3085 - 3092. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Toromanoff, P. Ammann, L. Mosekilde, J. S. Thomsen, and J.-L. Riond Parathyroid Hormone Increases Bone Formation and Improves Mineral Balance in Vitamin D-Deficient Female Rats Endocrinology, June 1, 1997; 138(6): 2449 - 2457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hollnagel, D. Schroder, and G. Gross Domain-specific Gene Activation by Parathyroid Hormone in Osteoblastic ROS17/2.8 Cells J. Biol. Chem., September 6, 1996; 271(36): 21870 - 21877. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |